Product Overview

Artesunate Injection IP 180 mg is an injectable antimalarial medicine used primarily for the treatment of severe malaria. Artesunate is a derivative of artemisinin and provides rapid reduction of malaria parasite levels in the bloodstream.

It acts against the blood-stage forms of Plasmodium parasites, including parasites responsible for severe malaria. Following administration, Artesunate is rapidly converted to its active metabolite, dihydroartemisinin (DHA), which exerts potent antimalarial activity.

The injectable formulation is particularly useful when rapid treatment is required or when a patient is unable to take oral medication. It may be administered through intravenous or intramuscular routes by qualified healthcare professionals.

Key Features

• Rapid-acting antimalarial formulation
• Designed for severe malaria management
• Suitable for intravenous or intramuscular administration
• Supports rapid reduction of parasite burden
• Supplied as an injectable formulation

Uses

• Severe malaria
• Malaria requiring injectable antimalarial therapy
• Patients unable to tolerate oral antimalarial medicines

How It Works

Artesunate is converted into dihydroartemisinin, which acts against malaria parasites during their blood stages, helping rapidly reduce the parasite burden.

Possible Side Effects

• Nausea
• Vomiting
• Headache
• Dizziness
• Injection-site reactions
• Changes in blood cell counts

Precautions

• For administration by qualified healthcare professionals only
• Use strictly according to the prescribed treatment regimen
• Appropriate monitoring is required during treatment
• Follow-up antimalarial therapy may be required after injectable Artesunate
• Do not self-administer

Storage Instructions

Store in a cool, dry place protected from light and moisture. Keep out of reach of children and use before the expiry date mentioned on the packaging.